Results 111 to 120 of about 7,838 (234)

Cost‐Effectiveness of Control‐IQ+ Technology in Insulin‐Treated Patients With Type 2 Diabetes in the United States

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 6280-6290, July 2026.
ABSTRACT Objective Automated insulin delivery (AID) has been established as an effective therapy for individuals with type 1 diabetes. This analysis evaluates the clinical and economic outcomes of AID compared with multiple daily injections plus continuous glucose monitoring (MDI/CGM) in adults with type 2 diabetes. Materials and Methods The IQVIA CORE
Neda Al Rawashdh   +12 more
wiley   +1 more source

Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes.

open access: yes, 1997
OBJECTIVE: Insulin lispro is a rapid-acting analog of human insulin that can be used to target the postprandial rise in plasma glucose. We designed an open-label randomized crossover study of type 2 diabetic patients with secondary failure of ...
Feinglos, MN   +4 more
core   +1 more source

Addition of 20-kDa PEG to Insulin Lispro Alters Absorption and Decreases Clearance in Animals [PDF]

open access: yes, 2016
Purpose: Determine the pharmacokinetics of insulin peglispro(BIL) in 5/6-nephrectomized rats and study the absorption inlymph duct cannulated (LDC) sheep.
de Veer, Michael J.   +19 more
core   +2 more sources

Efficacy and safety of insulin lispro protamine suspension as basal supplementation in patients with type 2 diabetes

open access: yesTherapeutic Advances in Endocrinology and Metabolism, 2012
The three currently marketed long-acting insulin analogs, glargine, detemir and insulin lispro protamine suspension (ILPS), represent the most significant advances in basal insulin supplementation since the 1940s and 1950s and the introduction of the ...
Dario Giugliano, Katherine Esposito
doaj   +1 more source

Aspart and lispro insulin, is there any difference when used with an insulin pump treatment?

open access: yes, 2006
The DCC and the EDIC study studies showed the significance of intensive insulin treatment in reducing blood glucose levels and delaying the onset/progression of cardiovascular disease and microvascular complications. To minimise cardiovascular risk it is
Scaramuzza A.   +7 more
core   +1 more source

Initiation and intensification of insulin therapy in patients with type 2 diabetes mellitus: a budget impact analysis

open access: yesФармакоэкономика, 2017
To date, several options for starting and intensifying insulin therapy in patients with type 2 diabetes mellitus (T2DM) have been proposed. Meta-analyzes of the recent results shows that, with adequate use, all these regimens have the similar efficacy ...
E. V. Biryukova, V. I. Ignat’eva
doaj   +1 more source

Congenital anomaly rate in offspring of mothers with diabetes treated with insulin lispro during pregnancy

open access: yes, 2004
Aim To determine the rate of major congenital anomalies in offspring of a large group of women with diabetes mellitus treated with insulin lispro (Humalog®). Methods This multinational, multicentre, retrospective study included mothers with diabetes
J. L. FRIAS   +11 more
core   +1 more source

A simple dilute and shoot methodology for the identification and quantification of illegal insulin

open access: yesJournal of Pharmaceutical Analysis, 2016
The occurrence of illegal medicines is a well-established global problem and concerns mostly small molecules. However, due to the advances in genomics and recombinant expression technologies there is an increased development of polypeptide therapeutics ...
Celine Vanhee   +4 more
doaj   +1 more source

Cardioprotective role of insulin: Advantage analogues

open access: yesJournal of Research in Medical Sciences, 2012
Aim: Type II diabetes mellitus (DM) increases the risk of cardiovascular disease. Treatment with insulin substantially reduces C - reactive protein (CRP) because of its anti-atherosclerotic action.
Rituparna Maiti   +5 more
doaj  

Cost-effectiveness of insulin analogs from the perspective of the Brazilian public health system

open access: yesBrazilian Journal of Pharmaceutical Sciences, 2017
Human insulin is provided by the Brazilian Public Health System (BPHS) for the treatment of diabetes, however, legal proceedings to acquire insulin analogs have burdened the BPHS health system.
Maurílio de Souza Cazarim   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy